These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18378908)

  • 1. Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus.
    Bobardt MD; Cheng G; de Witte L; Selvarajah S; Chatterji U; Sanders-Beer BE; Geijtenbeek TB; Chisari FV; Gallay PA
    Proc Natl Acad Sci U S A; 2008 Apr; 105(14):5525-30. PubMed ID: 18378908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral activity of virocidal peptide derived from NS5A against two different HCV genotypes: an in vitro study.
    El-Shenawy R; Tabll A; Bader El Din NG; El Abd Y; Mashaly M; Abdel Malak CA; Dawood R; El-Awady M
    J Immunoassay Immunochem; 2015; 36(1):63-79. PubMed ID: 24606010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.
    Cheng G; Montero A; Gastaminza P; Whitten-Bauer C; Wieland SF; Isogawa M; Fredericksen B; Selvarajah S; Gallay PA; Ghadiri MR; Chisari FV
    Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3088-93. PubMed ID: 18287023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent.
    Bobardt MD; Chatterji U; Schaffer L; de Witte L; Gallay PA
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2753-66. PubMed ID: 20439611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HSV neutralization by the microbicidal candidate C5A.
    de Witte L; Bobardt MD; Chatterji U; van Loenen FB; Verjans GM; Geijtenbeek TB; Gallay PA
    PLoS One; 2011 May; 6(5):e18917. PubMed ID: 21573158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HCV peptide (C5A), an amphipathic α-helical peptide of hepatitis virus C, is an activator of N-formyl peptide receptor in human phagocytes.
    Lin Q; Fang D; Hou X; Le Y; Fang J; Wen F; Gong W; Chen K; Wang JM; Su SB
    J Immunol; 2011 Feb; 186(4):2087-94. PubMed ID: 21228351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral peptide nanocomplexes as a potential therapeutic modality for HIV/HCV co-infection.
    Zhang J; Mulvenon A; Makarov E; Wagoner J; Knibbe J; Kim JO; Osna N; Bronich TK; Poluektova LY
    Biomaterials; 2013 May; 34(15):3846-57. PubMed ID: 23403120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Authentic Patient-Derived Hepatitis C Virus Infects and Productively Replicates in Primary CD4
    Skardasi G; Chen AY; Michalak TI
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29167333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly.
    Appel N; Zayas M; Miller S; Krijnse-Locker J; Schaller T; Friebe P; Kallis S; Engel U; Bartenschlager R
    PLoS Pathog; 2008 Mar; 4(3):e1000035. PubMed ID: 18369481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A synthetic codon-optimized hepatitis C virus nonstructural 5A DNA vaccine primes polyfunctional CD8+ T cell responses in wild-type and NS5A-transgenic mice.
    Holmström F; Pasetto A; Nähr V; Brass A; Kriegs M; Hildt E; Broderick KE; Chen M; Ahlén G; Frelin L
    J Immunol; 2013 Feb; 190(3):1113-24. PubMed ID: 23284053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Domain 3 of NS5A protein from the hepatitis C virus has intrinsic alpha-helical propensity and is a substrate of cyclophilin A.
    Verdegem D; Badillo A; Wieruszeski JM; Landrieu I; Leroy A; Bartenschlager R; Penin F; Lippens G; Hanoulle X
    J Biol Chem; 2011 Jun; 286(23):20441-54. PubMed ID: 21489988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Priming and stimulation of hepatitis C virus-specific CD4+ and CD8+ T cells against HCV antigens NS4, NS5a or NS5b from HCV-naive individuals: implications for prophylactic vaccine.
    Li W; Krishnadas DK; Kumar R; Tyrrell DL; Agrawal B
    Int Immunol; 2008 Jan; 20(1):89-104. PubMed ID: 18006878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient transfer of HIV-1 in trans and in cis from Langerhans dendritic cells and macrophages to autologous T lymphocytes.
    Peressin M; Proust A; Schmidt S; Su B; Lambotin M; Biedma ME; Laumond G; Decoville T; Holl V; Moog C
    AIDS; 2014 Mar; 28(5):667-77. PubMed ID: 24451159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of primary human T cell responses against hepatitis C virus-derived antigens NS3 or core by autologous dendritic cells expressing hepatitis C virus antigens: potential for vaccine and immunotherapy.
    Li W; Krishnadas DK; Li J; Tyrrell DL; Agrawal B
    J Immunol; 2006 May; 176(10):6065-75. PubMed ID: 16670315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broadly neutralizing antibody VRC01 prevents HIV-1 transmission from plasmacytoid dendritic cells to CD4 T lymphocytes.
    Su B; Lederle A; Laumond G; Ducloy C; Schmidt S; Decoville T; Moog C
    J Virol; 2014 Sep; 88(18):10975-81. PubMed ID: 24965460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response.
    Paterson M; Laxton CD; Thomas HC; Ackrill AM; Foster GR
    Gastroenterology; 1999 Nov; 117(5):1187-97. PubMed ID: 10535883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.
    Sede M; Laufer N; Ojeda D; Gun A; Cahn P; Quarleri J
    Arch Virol; 2013 Sep; 158(9):1907-15. PubMed ID: 23553458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV transmission from infected CD4+ T cells to allogenic T and dendritic cells is inhibited by broadly neutralizing antibodies.
    Ducloy C; Su B; Mayr L; Klingler J; Decoville T; Schmidt S; Laumond G; Salomé N; Bahram S; Moog C
    AIDS; 2018 Jun; 32(10):1239-1245. PubMed ID: 29683853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational design of peptides with anti-HCV/HIV activities and enhanced specificity.
    Li GR; He LY; Liu XY; Liu AP; Huang YB; Qiu C; Zhang XY; Xu JQ; Yang W; Chen YX
    Chem Biol Drug Des; 2011 Nov; 78(5):835-43. PubMed ID: 21801309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.